Preparation and solid state characterization of atorvastatin nanosuspensions for enhanced solubility and dissolution

International Journal of PharmTech Research

Volumn 1, Issue 4, 2009, Pages 1725-1730

  Arunkumar, N ^a   Deecaraman, M ^b   Rani, C ^c   Mohanraj, K P ^d   Venkates Kumar, K ^a  

^a KMCH COLLEGE OF PHARMACY   (India)

^b DR M G R EDUCATIONAL AND RESEARCH INSTITUTE   (India)

^c Cherraan's College of Pharmacy   (India)

^d JADAVPUR UNIVERSITY   (India)

Author keywords

Atorvastatin; Crystallinity; Dissolution; Drugs; High pressure homogenization; Nanoparticles

Indexed keywords

ATORVASTATIN; NANOPARTICLE;

ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; NANOPHARMACEUTICS; PARTICLE SIZE; SOLID STATE; THERMOGRAVIMETRY; X RAY DIFFRACTION;

EID: 77953466987     PISSN: None     EISSN: 09744304     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Han, H.-K., Choi, H.-K. Improved absorption of meloxicam via salt formation with ethanolamines. Eur. J. Pharm. Biopharm., 2007, 65, 99-103.
2. Choi, W.S., Kim, H.I., Kwak, S.S., Chung, H.Y., Chung, H.Y., Yamamoto, K., Oguchi, T., Tozuka, Y., Yonemochi, E., Terada, K. Amorphous ultrafine particle preparation for improvement of bioavailability of insoluble drugs: grinding characteristics of fine grinding mills. Int. J. Miner. Process. 2004, 74, S165-S172.
3. Paradkar, A., Ambike, A., Jadhav, B., Mahadik, K. Characterization of curcumin-PVP solid dispersion obtained by spray drying. Int. J. Pharm., 2004, 271, 281-286.
4. Chen, Y., Zhang, G., Neilly, J., Marsh, K., Mawhinney, D., Sanzgiri, Y. Enhancing the bioavailability of ABT-963 using solid dispersion containing Pluronic F-68. Int. J. Pharm., 2004, 286, 69-80.
5. Anzai, K., Mizoguchi, J., Yanagi, T., Hirayama, F., Arima, H., Uekama, K. Improvement of dissolution properties of a new Helicobacter pylori eradicating agent (TG44) by inclusion complexation with beta-cyclodextrin. Chem. Pharm. Bull. (Tokyo), 2007, 55, 1466-1470.
6. Jun, S., Kim, M., Kim, J., Park, H., Lee, S., Woo, J., Hwang, S. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. Eur. J. Pharm. Biopharm., 2007, 66, 413-421.
7. Shen, H., Zhong, M. Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin. J. Pharm. Pharmacol., 2006, 58, 1183-1191.
8. Park,M., Ren, S., Lee, B. In vitro and in vivo comparative study of itraconazole bioavailability when formulated in highly soluble self-emulsifying system and in solid dispersion. Biopharm. Drug Dispos., 2007, 28, 199-207.
9. Farinha, A., Bica, A., Tavares, P. Improved bioavailability of amicronizedmegestrol acetate tablet formulation in humans. Drug Dev. Ind. Pharm., 2000, 26,567-570.
10. Kim,M.-S., Lee, S., Park, J.-S.,Woo, J.-S., Hwang, S.-J. Micronization of cilostazol using supercritical antisolvent (SAS) process: effect of process parameters. Powder Technol., 2007, 177, 64-70. (Pubitemid 47224964)
11. Grau, M.J., Kayser, O., Muller, R.H. Nanosuspensions of poorly soluble drugs - reproducibility of small scale production. Int. J. Pharm., 2000, 196, 155-159.
12. Lipinski, C., Lombardo, F., Dominy, B., Feeney, P. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 2001, 46, 3-26.
13. Sato, T., Okada,A., Sekiguchi, K., Tsuda,Y. Difference inphysico-pharmaceutical properties between crystalline and non-crystalline 9,3-- diacetylmidecamycin.Chem. Pharm. Bull. (Tokyo), 1981, 29, 2675-2682.
14. Hancock, B., Parks, M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res., 2000, 17, 397-404.
15. Lennernas, H. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet., 2003, 42, 1141-1160.
16. Wu, X., Whit.eld, L.R., Stewart, B.H. Atorvastatin transport in the Caco-2 Cell Model: contributions of P-glycoprotein and the proton-monocarboxylic acid cotransporter. Pharm. Res., 2000, 17, 209-215.
17. Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., Bernini, F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther., 1999, 84, 413-428.
18. Kim, M.-S., Jin, S.-J., Kim, J.-S., Park, H.J., Song, H.-S., Neubertb, R.H.H., Hwang, S.-J. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur. J. Pharm. Biopharm.. 2008, 69, 454-465.
19. J.Hecq, M.Deleers, D.Fanara, H.Vrandex, K.Amighi. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int J Pharm., 2005, 299; 167-177.
20. Kocbek P, Baumgartner S, Kristi J. Preparation and evaluation of nanosuspensions for enhancing dissolution of poorly soluble drugs. Int J Pharm., 2006, 312 (1-2), 179-186.
21. Yuichi T, Atsutoshi I, Hiiroko S, Toshio O, Keiji Y. Characterization and quantitation of Clarithromycin polymorphs by powder X-Ray diffractometry and solid state NMR spectroscopy. Chem Pharm Bull., 2002, 50:1128-1130.
22. Kim J.S., Kim M.S., Park H.J., Shun Ji-Jin, Sibeum L., Hwang S J. Physiochemical properties and oral bioavailability of amorphous atrovastatin hemi-calcium using spray-drying and SAS process. Int. J. Pharm., 2008, 359, 211-219.
23. Elamin, A.A., Ahlneck, C., Alderborn, G., Nystrom, C. Increased metastable solubility of milled griseofulvin, depending on the formation of a disordered surface structure. Int. J. Pharm., 1994, 111, 159-170.
24. Chawla, G., Bansal, A. A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug. Eur. J. Pharm. Sci., 2007, 32, 45-57.